IPHS 10Q 09.30.12
Table of Contents

 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _______________________________________
FORM 10-Q
 ___________________________________________
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2012
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from              to               .
Commission File Number 001-33124
 ___________________________________________
INNOPHOS HOLDINGS, INC.
(Exact Name of Registrant as Specified in its Charter)
 ___________________________________________
 
Delaware
 
20-1380758
(State or Other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification No.)
 
 
259 Prospect Plains Road
Cranbury, New Jersey
 
08512
(Address of Principal Executive Offices)
 
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (609) 495-2495
 ____________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  o    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “accelerated filer,” “large accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
x
  
Accelerated Filer
o
Non-accelerated filer
o
  
Smaller reporting company
o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x
As of September 30, 2012, the registrant had 21,719,965 shares of common stock outstanding.
 


Table of Contents

TABLE OF CONTENTS
 
 
 
Page
 
 
 
 
 
Item 1.
Item 2.
Item 3.
Item 4.
 
 
 
 
 
 
 
 
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
 
 
 
 


Page 2 of 34



Table of Contents

PART I
 
ITEM 1.
FINANCIAL STATEMENTS
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
 
 
September 30,
2012
 
December 31,
2011
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
36,571

 
$
35,242

Accounts receivable, net
93,984

 
104,421

Inventories
154,240

 
169,728

Other current assets
78,493

 
75,316

Total current assets
363,288

 
384,707

Property, plant and equipment, net
185,876

 
187,421

Goodwill
68,047

 
61,587

Intangibles and other assets, net
60,069

 
53,300

Total assets
$
677,280

 
$
687,015

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Current portion of long-term debt
$
4,000

 
$
4,000

Accounts payable, trade and other
35,861

 
32,640

Other current liabilities
48,508

 
71,609

Total current liabilities
88,369

 
108,249

Long-term debt
113,000

 
148,000

Other long-term liabilities
36,866

 
37,558

Total liabilities
$
238,235

 
$
293,807

Commitments and contingencies (note 12)

 

Common stock, par value $.001 per share; authorized 100,000,000 shares; issued 22,020,597 and 21,770,641 shares; outstanding 21,719,965 and 21,620,119 shares
22

 
22

Paid-in capital
115,792

 
112,193

Common stock held in treasury, at cost (300,632 and 150,522 shares)
(13,411
)
 
(6,156
)
Retained earnings
340,961

 
292,144

Accumulated other comprehensive loss
(4,319
)
 
(4,995
)
Total stockholders' equity
439,045

 
393,208

Total liabilities and stockholders' equity
$
677,280

 
$
687,015


See notes to condensed consolidated financial statements

Page 3 of 34



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Income (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)
 
 
Three months ended
 
Nine months ended
 
September 30,
2012
 
September 30,
2011
 
September 30,
2012
 
September 30,
2011
Net sales
$
211,188

 
$
202,102

 
$
653,620

 
$
601,327

Cost of goods sold
168,409

 
152,872

 
512,605

 
445,604

Gross profit
42,779

 
49,230

 
141,015

 
155,723

Operating expenses:
 
 
 
 
 
 
 
Selling, general and administrative
17,417

 
15,343

 
49,687

 
46,954

Research & development expenses
776

 
762

 
2,320

 
2,205

Total operating expenses
18,193

 
16,105

 
52,007

 
49,159

Operating income
24,586

 
33,125

 
89,008

 
106,564

Interest expense, net
1,314

 
1,502

 
4,536

 
4,087

Foreign exchange (gains) losses
(1,800
)
 
1,459

 
(2,199
)
 
2,017

Income before income taxes
25,072

 
30,164

 
86,671

 
100,460

Provision for income taxes
8,366

 
11,307

 
25,873

 
34,888

Net income
$
16,706

 
18,857

 
$
60,798

 
65,572

Net income attributable to common shareholders
$
16,695

 
$
18,857

 
$
60,758

 
$
65,572

Per share data (note 2):
 
 
 
 
 
 
 
Income per share:
 
 
 
 
 
 
 
Basic
$
0.77

 
$
0.87

 
$
2.79

 
$
3.02

Diluted
$
0.74

 
$
0.84

 
$
2.70

 
$
2.90

Weighted average shares outstanding:
 
 
 
 
 
 
 
Basic
21,807,013

 
21,691,892

 
21,804,415

 
21,719,580

Diluted
22,500,262

 
22,557,661

 
22,519,360

 
22,604,845

 
 
 
 
 
 
 
 
Other comprehensive income (loss), net of tax:
 
 
 
 
 
 
 
Change in interest rate swaps, (net of tax $136, ($230), $312 and ($589))
$
221

 
$
(375
)
 
$
509

 
$
(962
)
Change in pension and post-retirement plans, (net of tax ($18), $76, $70 and $319)
(80
)
 
223

 
167

 
652

Other comprehensive income (loss), net of tax
$
141

 
$
(152
)
 
$
676

 
$
(310
)
Comprehensive income
$
16,847

 
$
18,705

 
$
61,474

 
$
65,262


See notes to condensed consolidated financial statements

Page 4 of 34



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in thousands)
 
 
Nine months ended
 
September 30,
2012
 
September 30,
2011
Cash flows from operating activities
 
 
 
Net income
$
60,798

 
$
65,572

Adjustments to reconcile net income to net cash provided from operating activities:
 
 
 
Depreciation and amortization
32,118

 
32,443

Amortization of deferred financing charges
428

 
461

Deferred income tax (benefit) provision
(1,545
)
 
6,378

Deferred profit sharing

 
395

Share-based compensation
3,319

 
5,122

Changes in assets and liabilities:
 
 
 
Decrease (increase) in accounts receivable
11,278

 
(10,870
)
Decrease (increase) in inventories
17,508

 
(34,747
)
(Increase) decrease in other current assets
(3,138
)
 
9,503

Increase (decrease) in accounts payable
2,844

 
(443
)
(Decrease) increase in other current liabilities
(18,933
)
 
4,731

Changes in other long-term assets and liabilities
(3,884
)
 
(3,111
)
Net cash provided from operating activities
100,793

 
75,434

Cash flows used for investing activities:
 
 
 
Capital expenditures
(15,997
)
 
(27,247
)
Investment in AMT
(27,093
)
 

Net cash used for investing activities
(43,090
)
 
(27,247
)
Cash flows used for financing activities:
 
 
 
Proceeds from exercise of stock options
381

 
484

Long-term debt borrowings
15,000

 

Long-term debt repayments
(50,000
)
 
(8,000
)
Excess tax benefits from exercise of stock options
2,681

 
2,487

Common stock repurchases
(7,255
)
 
(6,156
)
Dividends paid
(17,181
)
 
(14,517
)
Net cash used for financing activities
(56,374
)
 
(25,702
)
Net change in cash
1,329

 
22,485

Cash and cash equivalents at beginning of period
35,242

 
63,706

Cash and cash equivalents at end of period
$
36,571

 
$
86,191


See notes to condensed consolidated financial statements

Page 5 of 34



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Statement of Stockholders’ Equity (Unaudited)
(Dollars and shares in thousands)
 
Number of
Common
Shares
 
Common
Stock
 
Retained
Earnings
 
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Income/(Loss)
 
Total
Shareholders'
Equity
Balance, December 31, 2010
21,464

 
$
21

 
$
227,752

 
$
106,032

 
$
(3,089
)
 
$
330,716

Net income
 
 
 
 
86,522

 
 
 
 
 
86,522

Other comprehensive loss, (net of tax $836)
 
 
 
 
 
 
 
 
(1,906
)
 
(1,906
)
Proceeds from stock award exercises and issuances
300

 
1

 
 
 
(2,600
)
 
 
 
(2,599
)
Issuance of annual retainer stock to external Board of Directors
7

 
 
 
 
 
 
 
 
 

Share-based compensation
 
 
 
 
 
 
6,250

 
 
 
6,250

Excess tax benefits from exercise of stock options
 
 
 
 
 
 
2,511

 
 
 
2,511

Common stock repurchases
(151
)
 
 
 
 
 
(6,156
)
 
 
 
(6,156
)
Dividends declared
 
 
 
 
(22,130
)
 
 
 
 
 
(22,130
)
Balance, December 31, 2011
21,620

 
$
22

 
$
292,144

 
$
106,037

 
$
(4,995
)
 
$
393,208

Net income
 
 
 
 
60,798

 
 
 
 
 
60,798

Other comprehensive income, (net of tax $382)
 
 
 
 
 
 
 
 
676

 
676

Proceeds from stock award exercises and issuances
250

 
 
 
 
 
(2,401
)
 
 
 
(2,401
)
Share-based compensation
 
 
 
 
 
 
3,319

 
 
 
3,319

Excess tax benefits from exercise of stock options
 
 
 
 
 
 
2,681

 
 
 
2,681

Common stock repurchases
(150
)
 
 
 
 
 
(7,255
)
 
 
 
(7,255
)
Dividends declared
 
 
 
 
(11,981
)
 
 
 
 
 
(11,981
)
Balance, September 30, 2012
21,720

 
$
22

 
$
340,961

 
$
102,381

 
$
(4,319
)
 
$
439,045


See notes to condensed consolidated financial statements

Page 6 of 34



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

1. Basis of Statement Presentation
Summary of Significant Accounting Policies
The accompanying unaudited condensed consolidated financial statements of Innophos Holdings, Inc. and Subsidiaries, or Company, have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S.) for interim financial reporting and do not include all disclosures required by generally accepted accounting principles in the U.S. for annual financial reporting, and should be read in conjunction with the audited consolidated and combined financial statements of the Company at December 31, 2011 and for the three years then ended.
The accompanying unaudited condensed consolidated financial statements of the Company reflect all adjustments which management considers necessary for a fair statement of the results of operations for the interim periods and is subject to year end adjustments. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The December 31, 2011 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S.
Out of Period Adjustments
During the second quarter of fiscal 2012, we identified certain adjustments in our financial statements related to 2011 through the first quarter of fiscal 2012. We corrected the items during the second quarter of fiscal 2012, which had the effect of increasing cost of goods sold by $3.9 million, and decreasing net income by $2.6 million. The impact of these items for the nine months ended September 30, 2012 increased cost of goods sold by $2.4 million and decreased net income by $1.6 million. These prior period adjustments are not material to the financial results of the previously issued annual financial statements or current or previously issued interim financial statements. These adjustments are also not expected to be material to the full year 2012 financial statements.
Recently Issued Accounting Standards
Adopted
In May 2011, the FASB issued changes to conform existing guidance regarding fair value measurement and disclosure between U.S. GAAP and International Financial Reporting Standards. These changes both clarify the FASB's intent about the application of existing fair value measurement and disclosure requirements and amend certain principles or requirements for measuring fair value or for disclosing information about fair value measurements. The clarifying changes relate to the application of the highest and best use and valuation premise concepts, measuring the fair value of an instrument classified in a reporting entity's shareholders' equity, and disclosure of quantitative information about unobservable inputs used for Level 3 fair value measurements. The amendments relate to measuring the fair value of financial instruments that are managed within a portfolio; application of premiums and discounts in a fair value measurement; and additional disclosures concerning the valuation processes used and sensitivity of the fair value measurement to changes in unobservable inputs for those items categorized as Level 3, a reporting entity's use of a nonfinancial asset in a way that differs from the asset's highest and best use, and the categorization by level in the fair value hierarchy for items required to be measured at fair value for disclosure purposes only. These changes become effective for the Company on January 1, 2012. The implementation of this standard did not have a material impact on the Company's consolidated financial position and results of operations.
In September 2011, the FASB issued amendments to the goodwill impairment guidance which provides an option for companies to use a qualitative approach to test goodwill for impairment if certain conditions are met. The amendments are effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011 (early adoption is permitted). The implementation of this standard did not have a material impact on the Company's consolidated financial position and results of operations.
Issued but not yet adopted
In July 2012, the Financial Accounting Standards Board issued updated guidance on the periodic testing of indefinite-lived intangible assets for impairment. The updated guidance gives companies the option to perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount and, thus, whether further impairment testing is necessary. The updated accounting guidance is effective for fiscal years beginning after

Page 7 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

September 15, 2012, with early adoption permitted. The implementation of this standard will not have a material impact on the Company's consolidated financial position and results of operations.



2. Earnings per share (EPS)
The Company accounts for earnings per share in accordance with ASC 260 and related guidance, which requires two calculations of earnings per share (EPS) to be disclosed: basic EPS and diluted EPS. Under ASC Subtopic 260-10-45, as of January 1, 2009 unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as our restricted stock, are considered participating securities for purposes of calculating EPS. Under the two-class method, a portion of net income is allocated to these participating securities and therefore is excluded from the calculation of EPS allocated to common stock, as shown in the table below.
The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends attributable to unvested shares. The denominator for basic earnings per share is the weighted average number of common stock outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted for the effect of dilutive outstanding stock options, performance share awards and restricted stock awards.
The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-class method:
 
 
Three Months Ended
 
Nine Months Ended
 
September 30, 2012
 
September 30, 2011
 
September 30, 2012
 
September 30, 2011
Net income
$
16,706

 
$
18,857

 
$
60,798

 
$
65,572

Less: earnings attributable to unvested shares
(11
)
 

 
(40
)
 

Net income available to common shareholders
$
16,695

 
$
18,857

 
$
60,758

 
$
65,572

Weighted average number of common and potential common shares outstanding:
 
 
 
 
 
 
 
Basic number of common shares outstanding
21,807,013

 
21,691,892

 
21,804,415

 
21,719,580

Dilutive effect of stock equivalents
693,249

 
865,769

 
714,945

 
885,265

Diluted number of weighted average common shares outstanding
22,500,262

 
22,557,661

 
22,519,360

 
22,604,845

Earnings per common share:
 
 
 
 
 
 
 
Earnings per common share—Basic
$
0.77

 
$
0.87

 
$
2.79

 
$
3.02

Earnings per common share—Diluted
$
0.74

 
$
0.84

 
$
2.70

 
$
2.90

 
 
 
 
 
 
 
 
Total outstanding options, performance share awards and unvested restricted stock not included in the calculation of diluted earnings per share as the effect would be anti-dilutive
387,878

 
422,734

 
366,182

 
403,238



Page 8 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


3. Dividends
The following is the dividend activity for the three and nine months ended September 30, 2012 and September 30, 2011: 
 
Three Months Ended
 
Nine Months Ended
 
September 30
 
September 30
 
2012
 
2011
 
2012
 
2011
Dividends declared – per share
$

 
$
0.25

 
$
0.54

 
$
0.75

Dividends declared – aggregate

 
5,442

 
11,776

 
16,309

Dividends paid – per share
0.27

 
0.25

 
0.79

 
0.67

Dividends paid – aggregate
5,891

 
5,442

 
17,181

 
14,517


We are a holding company that does not conduct any business operations of our own. As a result, we are dependent upon cash dividends, distributions and other transfers from our subsidiaries, most directly Innophos, Inc., our primary operating subsidiary, and Innophos Investments Holdings, Inc., its parent, to make dividend payments on our Common Stock.
On October 26, 2012, the Company's Board of Directors declared an increase to its dividend to $0.35 per share to be paid on November 30, 2012 to shareholders of record on November 16, 2012.


4. Stockholders’ Equity / Stock-Based Compensation
Our compensation programs include share-based payments. The primary share-based awards and their general terms and conditions currently in effect are as follows:
Stock options, which entitle the holder to purchase, after the end of a vesting term, a specified number of shares of the Company’s common stock at an exercise price per share set equal to the market price of the Company’s common stock on the date of grant.
Performance share awards which entitle the holder to receive, at the end of a vesting term, a number of shares of the Company’s common stock, within a range of shares from zero to a specified maximum (generally 200%), calculated using a combination of performance indicators as defined solely by reference to the Company’s own activities. Amounts equivalent to dividends will accrue over the performance period and are paid on performance share awards when vested and distributed.
Restricted stock grants, which entitle the holder to receive, at the end of each vesting term, a specified number of shares of the Company's common stock, and which also entitle the holder to receive dividends paid on such grants throughout the vesting period.
Annual stock retainer grants, which entitle independent members of the Board of Directors to receive a number of shares of the Company’s common stock equal to a fixed retainer value.
 
Restricted Stock
On March 30, 2012 there were a total of 14,370 restricted shares granted to certain employees with a fair value of $0.7 million. These awards are classified as equity awards and vest annually over three years. The related compensation expense is based on the date of grant share price of $50.12. The compensation expense is amortized on a straight-line basis over the requisite vesting period and accelerated for those employees that are retirement eligible during the vesting period.
Stock Options
On March 30, 2012 the Company granted 39,683 non-qualified stock options at an exercise price of $50.12 per share to certain employees with a fair value of $0.8 million. The non-qualified stock options vest annually over three years with a March 30, 2022 expiration date.
The fair value of the options granted during 2012 was determined using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model were as follows:
 

Page 9 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Non-qualified stock options
 
Expected volatility
53.2
%
Dividend yield
2.4
%
Risk-free interest rate
1.3
%
Expected term (years)
6

Weighted average grant date fair value of stock options
$
20.41

For the 2012 grants the Company had chosen a blended volatility which consists of 50% historical volatility average of a peer group and 50% historical volatility of Innophos. The expected term for the stock options is based on the simplified method since the Company has limited data on the exercises of stock options. These stock options qualify as “plain vanilla” stock options in accordance with SAB 110. The dividend yield is the expected annual dividend payments divided by the average stock price up to the date of grant. The risk-free interest rates are derived from the U.S. Treasury securities in effect on the date of grant whose maturity period equals the options expected term. The Company applies an expected forfeiture rate to stock-based compensation expense. The estimate of the forfeiture rate is based primarily upon historical experience of employee turnover. As actual forfeitures become known, stock-based compensation expense is adjusted accordingly.
Performance Share Awards
On March 30, 2012, the Company granted 43,106 performance shares to certain employees with a fair value of $2.2 million. The performance shares vest at the end of the three year performance cycle and the number of shares distributable depends on the extent to which the Company attains pre-established performance goals. Amounts equivalent to declared dividends will accrue on the performance shares and will vest over the same period.
In connection with the vesting of the performance share awards issued in 2009, the Company issued 136,423 shares of common stock, net of minimum tax withholdings, to certain employees as required under the terms of the plan in the first quarter of 2012.
Stock Grants
In May 2012 the six external members of the Board of Directors were each granted 1,275 shares of the Company's common stock with an aggregated fair value of $0.4 million which immediately vested as part of their director fees.
The following table summarizes the components of stock-based compensation expense, all of which has been classified as selling, general and administrative expense:
 
 
Three Months Ended
 
Nine Months Ended
 
September 30,
2012
 
September 30,
2011
 
September 30,
2012
 
September 30,
2011
Stock options
$
291

 
$
288

 
$
1,147

 
$
1,225

Restricted stock
57

 

 
180

 
6

Performance shares
643

 
806

 
1,632

 
3,591

Stock grants

 

 
360

 
300

Total share-based compensation expense
$
991

 
$
1,094

 
$
3,319

 
$
5,122

 During 2011 the Board of Directors authorized a repurchase program for Company common stock of up to $50 million. Under the program, shares will be repurchased from time to time at management's discretion, either through open market transactions, block purchases, private transactions or other means and will be funded through existing liquidity and cash from operations. A five year time limit has been set for the expiration of the program as initially structured. The timing of repurchases and the exact number of shares of common stock to be purchased will depend upon market conditions and other factors. However, annual repurchase amounts are expected at a minimum to be sufficient to reduce significantly, or eliminate, earnings per share dilution caused by shares issued upon the exercise of stock options and in connection with other equity based compensation plans. Treasury stock is recognized at the cost to reacquire the shares. During the third quarter of 2012, the

Page 10 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Company repurchased 150,000 shares of its common stock on the open market at an average price of $48.37 per share or $7.3 million.

5. Inventories
Inventories consist of the following:
 
 
September 30,
2012
 
December 31,
2011
Raw materials
$
39,454

 
$
44,937

Finished products
105,878

 
116,488

Spare parts
8,908

 
8,303

 
$
154,240

 
$
169,728


Inventory reserves for excess quantities, obsolescence or shelf-life expiration as of September 30, 2012 and December 31, 2011 were $11,849 and $9,911, respectively.

6. Other Current Assets
Other current assets consist of the following:
 
 
September 30,
2012
 
December 31,
2011
Rhodia indemnity receivable for CNA water tax claims (see note 12)
$

 
$
13,571

Creditable taxes (value added taxes)
31,957

 
20,473

Vendor inventory deposits (prepaid)
12,036

 
19,671

Prepaid income taxes
17,324

 
4,829

Other prepaids
2,397

 
2,585

Deferred income taxes
10,348

 
10,347

Other
4,431

 
3,840

 
$
78,493

 
$
75,316


Page 11 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


7. Intangibles and Other Assets, net
Intangibles and other assets consist of the following:
 
 
Useful life
(years)
 
September 30,
2012
 
December 31,
2011
Developed technology and application patents, net of accumulated amortization of $15,585 for 2012 and $13,980 for 2011
7-20
 
$
24,305

 
$
24,010

Customer relationships, net of accumulated amortization of $7,203 for 2012 and $5,956 for 2011
5-15
 
18,907

 
13,333

Tradenames and license agreements, net of accumulated amortization of $4,676 for 2012 and $4,246 for 2011
5-20
 
6,474

 
5,974

Non-compete agreements, net of accumulated amortization of $636 for 2012 and $568 for 2011
5-10
 
184

 
73

Total intangibles
 
 
$
49,870

 
$
43,390

Deferred financing costs, net of accumulated amortization of $1,265 for 2012 and $837 for 2011 (see note 9)
 
 
$
1,563

 
$
1,991

Deferred income taxes
 
 
5,768

 
5,450

Other Assets
 
 
2,868

 
2,469

Total other assets
 
 
$
10,199

 
$
9,910

 
 
 
$
60,069

 
$
53,300


8. Other Current Liabilities
Other current liabilities consist of the following:
 
 
September 30,
2012
 
December 31,
2011
CNA water tax claims (see Note 12)
$
10,592

 
$
31,523

Payroll related
10,820

 
11,708

Taxes
9,292

 
5,885

Benefits and pensions
5,884

 
7,717

Freight and rebates
4,962

 
4,418

Dividends payable

 
5,405

Other
6,958

 
4,953

 
$
48,508

 
$
71,609


9. Short-term Borrowings, Long-Term Debt, and Interest Expense
Short-term borrowings and long-term debt consist of the following:
 
 
September 30,
2012
 
December 31,
2011
Term loan due 2015
$
92,000

 
$
95,000

Revolver borrowings under the credit facility
25,000

 
57,000

Total borrowings
$
117,000

 
$
152,000

Less current portion
4,000

 
4,000

Long-term debt
$
113,000

 
$
148,000


The Company's credit facility includes a term loan of $100.0 million and a revolving line of credit from the Lenders of up to $125.0 million, including a $20.0 million letter of credit sub-facility, all maturing on August 26, 2015. Prepayments of the term loan are required at the rate of 1% of original principal amount per quarter beginning on December 31, 2010.
As of September 30, 2012, $92.0 million was outstanding under the Term Loan and $25.0 million was outstanding under the revolving line of credit, both of which approximate fair value because they have a floating interest rate, level 2 input within

Page 12 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

the fair value hierarchy, with total availability at $98.1 million, taking into account $1.9 million in face amount of letters of credit issued under the sub-facility. The current weighted average interest rate for all debt is 4.1%.
In the third quarter of 2010 the Company entered into an interest rate swap with an original notional amount of $100.0 million adjusting quarterly consistent with the Term Loan, with a fixed rate of 1.994% plus the applicable margin on the debt expiring in August 2015. The Company exercised its right to cancel the interest rate swap with no fee on September 28, 2012.
We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status.
Total interest paid by the Company for all indebtedness for the nine months ended September 30, 2012 and September 30, 2011 was $4,355 and $4,504.
As of September 30, 2012, the Company was in full compliance with all debt covenant requirements.
 
Interest expense, net consists of the following:
 
 
Three months ended
 
Nine months ended
 
September 30,
2012
 
September 30,
2011
 
September 30,
2012
 
September 30,
2011
Interest expense
$
1,371

 
1,478

 
$
4,350

 
4,475

Deferred financing cost
141

 
149

 
428

 
461

Interest income
(11
)
 
(98
)
 
(55
)
 
(403
)
Less: amount capitalized for capital projects
(187
)
 
(27
)
 
(187
)
 
(446
)
Total interest expense, net
$
1,314

 
$
1,502

 
$
4,536

 
$
4,087


10. Other Long-Term Liabilities
Other long-term liabilities consist of the following:
 
 
September 30,
2012
 
December 31,
2011
Deferred income taxes
$
23,761

 
$
24,308

Pension and post retirement liabilities (U.S. and Canada only)
6,290

 
6,185

Environmental liabilities
1,100

 
1,100

Profit sharing and post employment liabilities
4,478

 
3,795

Other liabilities
1,237

 
2,170

 
$
36,866

 
$
37,558


11. Income Taxes
The effective income tax rate on income before taxes was approximately 30% for the nine months ended September 30, 2012 compared to approximately 35% for the comparable period in 2011. The variance in the effective tax rate is primarily due to the recording of an indemnity receivable related to the Mexican CNA Water Tax Claims (see note 12, Mexican CNA Water Tax Claims) being recorded as a discrete item for income tax provision purposes in the first quarter of 2012.
The Company does not have any material uncertain income tax positions in accordance with ASC 740-10-25. If any material uncertain tax positions did arise, the Company’s policy is to accrue associated penalties in selling, general and administrative expenses and to accrue interest in net interest expense. Currently, the Company is under examination, or has been contacted for examination, by certain foreign jurisdictions for its income tax returns for the years 2006 through 2009. As of September 30, 2012, our subsidiary, Innophos Mexicana requested a refund of $2.4 million for the 2009 tax year which is being disputed by the Mexican tax authorities. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. In addition, our subsidiary, Innophos Canada, Inc. was assessed approximately $4.0 million for the tax years 2006, 2007, and 2008 by the Canadian tax authorities. On April 27, 2012, Innophos Canada filed a response to the Canadian tax authorities for the above tax matter disputing the full assessment. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. Other than

Page 13 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

the assessments mentioned above, as of September 30, 2012, no significant adjustments have been proposed to the Company's tax positions and the Company currently does not anticipate any adjustments that would result in a material change to its financial position during the next twelve months.
Income taxes paid were $36,931 and $17,543 for the nine months ended September 30, 2012 and September 30, 2011, respectively.

12. Commitments and Contingencies
Environmental
The Company's operations are subject to extensive and changing federal and state environmental laws and regulations. The Company's manufacturing sites have an extended history of industrial use, and soil and groundwater contamination have or may have occurred in the past and might occur or be discovered in the future.
Liabilities for environmental matters are difficult to assess for numerous reasons, including the discovery of new remedial sites, discovery of new information and scarcity of reliable information pertaining to certain sites, improvements in technology, changes in environmental laws and regulations, numerous possible remedial techniques and solutions, difficulty in assessing the involvement of and the financial capability of other potentially responsible parties and the extended time periods over which remediation occurs. As the Company's environmental contingencies are more clearly determined, it is reasonably possible that amounts may need to be accrued. However, management does not believe, based on current information, that environmental remediation requirements will have a material impact on the Company's results of operations, financial position or cash flows.
Future environmental spending is probable at our site in Nashville, TN, the eastern portion of which had been used historically as a landfill, and a western parcel previously acquired from a third party, which reportedly had housed, but no longer does, a fertilizer and pesticide manufacturing facility. We have an estimated liability with a range of $0.9-$1.2 million. The remedial action plan for that site has yet to be finalized, and as such, the Company has recorded a liability, which represents the Company's best estimate, of $1.1 million as of September 30, 2012.
Litigation
2008 RCRA Civil Enforcement – Geismar, Louisiana plant
Following several inspections by the Environmental Protection Agency, or EPA, at our Geismar, LA purified phosphoric acid, or PPA, plant and related submissions we made to support claimed exemptions from the federal Resource, Conservation and Recovery Act, or RCRA, in March 2008, EPA referred our case to the Department of Justice, or DOJ, for civil enforcement. Although no citations were ever issued or formal proceedings instituted, the agencies claim we violate RCRA by failing to manage appropriately two materials that DOJ/EPA alleges are hazardous wastes. Those materials are: (i) Filter Material from an enclosed intermediate filtration step to further process green phosphoric acid we receive as raw material via pipeline from the adjacent site operated by an affiliate of Potash Corporation of Saskatchewan, or PCS; and (ii) Raffinate, a co-product we provide to PCS under a long-term contract we have with PCS.
Since referral of the case to DOJ, we and PCS have engaged in periodic discussions with DOJ/EPA and the Louisiana Department of Environmental Quality, or LDEQ, or collectively the Government Parties, in order to resolve the matter. In addition to asserting that the two materials in question are not hazardous wastes, we have also sought to demonstrate that both the nature and character of the materials as well as their use, handling and disposition were detailed in a solid waste permit amendment application filed in 1989 by PCS's predecessor, when our plant was first constructed, and approved by the LDEQ under the state RCRA program.
In the course of discussions with the Government Parties, the DOJ/EPA has required that we undertake, as an interim measure, the construction of a new filter unit that would replace the existing closed system and allow the removal and separate handling of the Filter Material. We built that unit, which is ready for commissioning and operation once appropriate agreements are reached with the Government Parties and PCS.
We and PCS also have initiated joint efforts to explore possible technical solutions to remaining concerns of the Government Parties, including Raffinate treatment. To date, treatment techniques for Raffinate have not yet been fully evaluated from a technological or cost standpoint. Based upon work so far, there appears to be at least one technically viable approach, but it has yet to be fully evaluated.

Page 14 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Even though the companies have conducted substantial technical work in an attempt to develop a feasible approach to address regulatory concerns, we cannot guarantee that our technical efforts will be successful, whether either party would be willing to implement solutions at what cost allocation or, depending on those factors and the Government Parties' position, whether this matter will be settled or will require litigation. Should litigation become necessary to defend our operations at Geismar as compliant with environmental laws and regulations or with PCS as to cost responsibility, no assurance can be given as to its outcome.
Based upon advice of our environmental counsel, we have determined that the risk of an effort by the Government Parties to shut down our Geismar plant or PCS's Geismar plant from which we obtain the green acid raw material is remote. In addition, we have concluded that the contingent liability arising from compliance costs for this matter as discussed above is neither remote nor probable, but is reasonably possible. On the assumption that “deep well injection” at the site is ultimately employed or required as the technologically acceptable approach for Raffinate, based on preliminary cost estimates to date, we estimate this technical approach to range from approximately $10 to $16 million.
Mexican CNA Water Tax Claims - 2005-2008
In January 2012, Fosfatados was served with CNA resolutions claiming higher water fees, surcharges and penalties for 2005 through 2008 for the total amount of approximately $10.6 million at current exchange rates (net of regulatory discounts), for which the Company has recorded an accrual. The Company has timely contested the resolutions in Mexican Courts and posted security for the amount claimed by granting liens, in accordance with Mexican law, on specified production assets located at its Coatzacoalcos plant.
Other Legal Matters
In March 2008, Sudamfos S.A., or Sudamfos, an Argentine phosphate producer, filed an arbitration before the ICC International Court of Arbitration, Paris, France, concerning an alleged agreement for our Mexicana subsidiary, Mexicana, to sell it 12,500 metric tons of phosphoric acid, but subsequently withdrew the proceeding. In October 2008, Mexicana filed suit in Mexico against Sudamfos to collect approximately $1.2 million representing the contract price for prior deliveries of acid for which Sudamfos had refused to pay. In October 2009, Sudamfos answered the suit and counterclaimed for $3.0 million based upon the agreement originally alleged in the arbitration. In subsequent proceedings including available appeals, Mexicana's claim was sustained and Sudamfos' counterclaim was denied. Mexicana has now begun formal collection proceedings against Sudamfos.
In addition, we are party to legal proceedings and contractual disputes that arise in the ordinary course of our business. Except as to the matters specifically discussed, management believes that these matters currently represent contingent liabilities that are not material. However, these matters cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, results of operations, financial condition, and/or cash flows.

Page 15 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


13. Pension Plans and Postretirement Benefits

Net periodic benefit expense for the United States plans:
 
For the three months ended September 30, 2012
 
For the three months ended September 30, 2011
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$

 
$
81

 
$
81

 
$

 
$
72

 
$
72

Interest cost
28

 
34

 
62

 
27

 
37

 
64

Expected return on assets
(28
)
 

 
(28
)
 
(18
)
 

 
(18
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
prior service cost

 
33

 
33

 

 
32

 
32

unrecognized (gain) loss
4

 
(7
)
 
(3
)
 

 
(15
)
 
(15
)
Net periodic cost
$
4

 
$
141

 
$
145

 
$
9

 
$
126

 
$
135

 
 
 
 
 
 
 
 
 
 
 
 
 
For the nine months ended September 30, 2012
 
For the nine months ended September 30, 2011
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$

 
$
243

 
$
243

 
$

 
$
219

 
$
219

Interest cost
82

 
106

 
188

 
83

 
111

 
194

Expected return on assets
(82
)
 

 
(82
)
 
(54
)
 

 
(54
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
prior service cost

 
97

 
97

 

 
99

 
99

unrecognized (gain) loss
10

 
(21
)
 
(11
)
 

 
(46
)
 
(46
)
Net periodic cost
$
10

 
$
425

 
$
435

 
$
29

 
$
383

 
$
412


In April 2012, Innophos contributed approximately $0.2 million to its U.S. defined benefit pension plan to satisfy the full year 2012 minimum contribution requirements.
Innophos made its entire cash contribution of $3.0 million for the U.S. defined contribution plan during the first quarter of 2012 for the plan year 2011.


Page 16 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Net periodic benefit expense for the Canadian plans:
 
For the three months ended September 30, 2012
 
For the three months ended September 30, 2011
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$
85

 
$
21

 
$
106

 
$
69

 
$
17

 
$
86

Interest cost
151

 
26

 
177

 
142

 
23

 
165

Expected return on assets
(236
)
 

 
(236
)
 
(238
)
 

 
(238
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
actuarial loss (gain)
65

 
11

 
76

 

 
7

 
7

prior service cost
26

 

 
26

 
26

 

 
26

net transition obligation

 
7

 
7

 
40

 
10

 
50

Exchange rate changes
122

 
22

 
144

 
(46
)
 
(10
)
 
(56
)
Net periodic cost
$
213

 
$
87

 
$
300

 
$
(7
)
 
$
47

 
$
40

 
 
 
 
 
 
 
 
 
 
 
 
 
For the nine months ended September 30, 2012
 
For the nine months ended September 30, 2011
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$
253

 
$
61

 
$
314

 
$
211

 
$
51

 
$
262

Interest cost
451

 
74

 
525

 
433

 
71

 
504

Expected return on assets
(706
)
 

 
(706
)
 
(726
)
 

 
(726
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
actuarial loss (gain)
195

 
35

 
230

 

 
23

 
23

prior service cost
78

 

 
78

 
80

 

 
80

net transition obligation

 
23

 
23

 
124

 
30

 
154

Exchange rate changes
142

 
29

 
171

 
140

 
(35
)
 
105

Net periodic cost
$
413

 
$
222

 
$
635

 
$
262

 
$
140

 
$
402

Innophos Canada, Inc. made cash contributions to its Canadian defined benefit plan of $0.6 million during the nine months ended September 30, 2012. Innophos Canada, Inc. plans to make additional cash contributions to its Canadian defined benefit plan of approximately $0.2 million during the remainder of 2012.

14. Segment Reporting
The company discloses certain financial and supplementary information about its reportable segments, revenue by products and revenues by geographic area. Operating segments are defined as components of an enterprise about which separate discrete financial information is evaluated regularly by the chief operating decision maker, in order to decide how to allocate resources and assess performance. The primary performance indicators for the chief operating decision maker are sales and operating income, with sales on a ship-from basis. All references to sales in this Form 10-Q, either on a ship-from or ship-to basis, are on the same basis of revenue recognition and are recognized when title and risk of loss passes to the customer, which occurs either upon shipment or delivery, depending upon the agreed sales terms with customers.
The Company's reportable segments reflect the core businesses in which Innophos operates and how it is managed. The Company reports its core specialty phosphates business separately from granular triple super-phosphate, or GTSP, and other non-specialty phosphate products (GTSP & Other). Kelatron and AMT are included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA, and STPP & Detergent Grade PPA. GTSP & Other includes fertilizer co-product GTSP and other non-specialty phosphate products.


Page 17 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

For the three months ended September 30, 2012
 
Specialty
Phosphates
US & Canada
 
Specialty
Phosphates
Mexico
 
GTSP &
Other
 
Eliminations
 
Total
Sales
 
$
144,664

 
$
41,222

 
$
25,302

 
$

 
$
211,188

Intersegment sales
 
370

 
14,087

 
57

 
(14,514
)
 

Total sales
 
$
145,034

 
$
55,309

 
$
25,359

 
$
(14,514
)
 
$
211,188

Operating income (b)
 
$
22,759

 
$
2,369

 
$
(542
)
 
$

 
$
24,586

Depreciation and amortization expense
 
$
5,732

 
$
3,670

 
$
1,160

 
$

 
$
10,562

 
 
 
 
 
 
 
 
 
 
 
For the three months ended September 30, 2011
 
Specialty
Phosphates
US & Canada
 
Specialty
Phosphates
Mexico
 
GTSP &
Other
 
Eliminations
 
Total
Sales
 
$
130,850

 
$
48,601

 
$
22,651

 
$

 
$
202,102

Intersegment sales
 
284

 
14,841

 
132

 
(15,257
)
 

Total sales
 
$
131,134

 
$
63,442

 
$
22,783

 
$
(15,257
)
 
$
202,102

Operating income (c)
 
$
21,331

 
$
7,143

 
$
4,651

 
$

 
$
33,125

Depreciation and amortization expense
 
$
4,864

 
$
4,909

 
$
1,753

 
$

 
$
11,526

 
 
 
 
 
 
 
 
 
 
 
For the nine months ended September 30, 2012
 
Specialty
Phosphates
US & Canada
 
Specialty
Phosphates
Mexico
 
GTSP &
Other
 
Eliminations
 
Total
Sales
 
$
432,528

 
$
139,951

 
$
81,141

 
$

 
$
653,620

Intersegment sales
 
1,218

 
45,082

 
320

 
(46,620
)
 

Total sales
 
$
433,746

 
$
185,033

 
$
81,461

 
$
(46,620
)
 
$
653,620

Operating income (a) (b)
 
$
70,262

 
$
17,156

 
$
1,590

 
$

 
$
89,008

Depreciation and amortization expense
 
$
17,280

 
$
11,233

 
$
3,605

 
$

 
$
32,118

 
 
 
 
 
 
 
 
 
 
 
For the nine months ended September 30, 2011
 
Specialty
Phosphates
US & Canada
 
Specialty
Phosphates
Mexico
 
GTSP &
Other
 
Eliminations
 
Total
Sales
 
$
393,262

 
$
132,634

 
$
75,431

 
$

 
$
601,327

Intersegment sales
 
1,056

 
35,522

 
312

 
(36,890
)
 

Total sales
 
$
394,318

 
$
168,156

 
$
75,743

 
$
(36,890
)
 
$
601,327

Operating income (c)
 
$
77,613

 
$
12,358

 
$
16,593

 
$

 
$
106,564

Depreciation and amortization expense
 
$
14,897

 
$
12,814

 
$
4,732

 
$

 
$
32,443


(a)
The nine months ended September 30, 2012 includes a $7.1 million benefit to earnings primarily for the settlement with Rhodia on their liability for the charges to be paid to the CNA for the CNA Fresh Water Claims in GTSP & Other.
(b)
The nine months ended September 30, 2012 includes $2.4 million of out of period cost in Mexico in GTSP & Other.
(c)
The three and nine months ended September 30, 2011 include a $0.3 million benefit and a $3.6 million benefit, respectively, to earnings related to updates to the provision for the CNA Fresh Water Claims in GTSP & Other.

Page 18 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


15. Acquisitions
The Company has made two recent acquisitions in the bioactive mineral ingredients sector. Bioactive mineral ingredients are mineral based ingredients for food, beverage and dietary supplement end markets that are manufactured to be readily digestible. Historically, Innophos has enjoyed a strong position in “macronutrients,” minerals such as calcium, magnesium and potassium that are required in relatively large amounts for a balanced diet. The human diet also requires smaller quantities of a wide range of other minerals such as chromium, selenium, zinc and iron classified as “micronutrients.” The acquisitions described below have created a strong position for Innophos in micronutrient bioactive mineral ingredients to complement the Company's existing strength in macronutrients.
In October 2011, Innophos acquired privately held Kelatron Corporation in a transaction accounted for under the acquisition method of accounting for business combinations. Kelatron, based in Ogden, Utah, is a leading producer of bioactive mineral nutrients sold into the nutritional and dietary supplements markets. The acquisition had a purchase price of approximately $21 million in cash, subject to working capital adjustments, and was funded from our revolving line of credit. Under the acquisition method of accounting, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date. The reported consolidated financial condition and results of operations after completion of the acquisition reflect those fair values, and Kelatron's results of operations have been included in the consolidated financial statements from the date of acquisition. The purchase accounting for the acquisition has been closed and immaterial adjustments were recognized in the second quarter of 2012.
In July 2012, Innophos purchased AMT Labs, Inc. and an affiliated company holding real property to support future expansion. AMT, a privately held company based in North Salt Lake, Utah, has been manufacturing high quality custom mineral ingredients for the food, beverage, confectionary and dietary supplement industries for more than 20 years. The combined purchase price was $27.0 million in cash, with $19.5 million being allocated to the AMT purchase and $7.5 million being allocated to the real estate entity, plus a contingent payment arrangement.The arrangement provides for payments of up to $3.0 million if certain new market development opportunities, measured by adjusted revenue, are realized following the acquisition. The fair value of the contingent consideration arrangement has been preliminarily set at $1.0 million based on probability of achievement and recorded at net present value, making for a total purchase price of $28.0 million. The cash was funded from our revolving line of credit, as well as cash from operations.
During the three months ended September 30, 2012, the Company's consolidated results of operations included revenues of $2.2 million with an immaterial effect on net income attributable to AMT.
The preliminary AMT purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective fair values summarized below (in thousands):
Cash
$
325

Accounts receivable
841

Inventory, including step up of $352
2,020

Other current assets
39

Property, plant and equipment
9,483

Goodwill
6,494

Intangible assets
9,830

Accounts payable
(377
)
Other current liabilities
(1,237
)
Total
$
27,418


The intangible assets acquired in the AMT purchase include the following (in thousands):

Page 19 of 34



Table of Contents
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

 
Useful life
(years)
 
Customer relationships
10-15
$
6,820

Developed technology
7
1,900

Tradename
5
930

Non-compete agreement
10
180

 
 
$
9,830

The allocation of the purchase price for the acquisition has been prepared on a preliminary basis and changes to that allocation may occur as additional information becomes available. The excess of purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition and will be included in the Specialty Phosphates US segment. The Company expects the goodwill created to be deductible for tax purposes. This transaction was treated as an asset purchase for U.S. federal tax purposes.
The customer relationships were valued based on the excess earnings method under the income approach which provides an estimate of the fair value based on a market participant. The after tax cash flows were discounted to present value using a 15.5% and 16.5% discount rate for direct customers and distributors, respectively.
Pro forma financial information (unaudited):
The following unaudited pro forma information presents the combined results of operations for the three and nine months ended September 30, 2012 and September 30, 2011 as if the acquisitions of Kelatron and AMT had been completed on January 1, 2011. The unaudited pro forma results do not reflect any material adjustments, operating efficiencies or potential cost savings which may result from the consolidation of operations.
 
Three months ended
 
Nine months ended
 
September 30,
2012
 
September 30,
2011
 
September 30,
2012
 
September 30,
2011
Revenues
$
211,382

 
$
208,117

 
$
660,380

 
$
622,214

Net income
$
16,902

 
$
18,199

 
$
60,500

 
$
66,070

Income per common share - Basic
$
0.78

 
$
0.84

 
$
2.77

 
$
3.04

Income per common share - Diluted
$
0.75

 
$
0.81

 
$
2.69

 
$
2.92



ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This discussion contains forward-looking statements about our markets, the demand for our products and services and our future results. We based these statements on assumptions that we consider reasonable. Actual results may differ materially from those suggested by our forward-looking statements for various reasons including those discussed in the “Risk Factors” and “Forward-Looking Statements” sections of this report.
Innophos is a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. Innophos combines more than a century of experience in specialty phosphate manufacturing with a growing capability in a broad range of other mineral ingredients to supply a product range produced to stringent regulatory manufacturing standards and the quality demanded by customers worldwide. Many of Innophos' products are application-specific compounds engineered to meet customer performance requirements and are often critical to the taste, texture and performance of foods, beverages, pharmaceuticals, oral care products and other applications. For example, Innophos products act as flavor enhancers in beverages, electrolytes in sports drinks, texture additives in cheeses, leavening agents in baked goods, pharmaceutical excipients, cleaning agents in toothpaste and provide a wide range of mineral fortification solutions for food, beverage and nutritional supplement manufacturers.


Page 20 of 34



Table of Contents


Recent Trends and Outlook

Market conditions for Specialty Phosphates are expected to continue at a similar level through the 2012 fourth quarter with demand expected to be similar or marginally below year ago levels. Management expects the US/Canada Specialty Phosphates business to continue achieving moderate organic year over year volume growth despite challenging external conditions, although on a sequential basis, volumes in the fourth quarter are typically 1-2% lower than the third quarter. Mexico Specialty Phosphates is expected to complete its subsequent planned maintenance outage activities during the fourth quarter according to schedule. Although the business is expected to restore fourth quarter volumes to the prior run rate, the ongoing maintenance program will limit the ability of the business to fully compensate for the shortfall in the third quarter.
Specialty Phosphates selling prices were 5% higher in the 2012 third quarter versus the same period last year, and the business is targeting further selling price increases in response to ongoing high levels for market raw material prices with a modest sequential benefit anticipated for the fourth quarter.
Maintenance spending, primarily for scheduled outages in the US and Mexico, along with exploration activities to support the evaluation of our mining concessions in Mexico, were in line with the $2 million expected, but more weighted towards maintenance. A similar level of expense is expected for the fourth quarter in these areas. Overall, therefore, management expects Specialty Phosphates operating performance in the 2012 fourth quarter to be broadly similar to the third quarter as improved Mexico Specialty Phosphate performance offsets the typical US/Canada seasonal volume decline. GTSP & Other operating performance is also expected to continue at approximately a break-even level through the fourth quarter.
Net debt (total debt less cash) increased by $17 million in the 2012 third quarter to $80 million resulting primarily from the $27 million acquisition of AMT and $7 million for the Company's previously announced stock repurchase program.
In July 2012, Innophos purchased AMT Labs, Inc. and an affiliated company holding real property to support future expansion. AMT, a privately held company based in North Salt Lake, Utah, has been manufacturing high quality custom mineral ingredients for the food, beverage, confectionary and dietary supplement industries for more than 20 years. AMT specializes in mineral ingredients essential to the human diet that are manufactured in chelates and other forms so as to be easily digested (bioactive).
Capital Expenditures
Capital expenditures were $6 million in the 2012 third quarter and management now expects to spend approximately $25 million for all of 2012. As previously reported, the reduced expectation for capital expenditures is attributable to delays in some projects stemming from changes in engineering specifications. Investment continues to be focused on capacity enhancements for US / Canada and Mexico Specialty Ingredients facilities, expanding geographically, including the investment in China, and enhancing Mexico's capability to process multiple grades of phosphate rock, consistent with the Company's supply chain diversification strategy.
Hurricane Sandy
No manufacturing or distribution centers were affected directly by Hurricane Sandy. Although the company's R&D and corporate headquarters in Cranbury, NJ were without power for the work week since the storm passed on October 29, 2012 the facility was back to full service on November 5th. The Company does not expect the storm's effect on fourth quarter earnings to be material, but, at this time, it is unable to fully assess the impact of Hurricane Sandy on customer demand.
 

Page 21 of 34



Table of Contents


Historical Performance
Results of Operations
The following table sets forth a summary of the Company’s operations and their percentages of total revenue for the periods indicated. (dollars in millions):
 
 
Three Months Ended
 
Three Months Ended
 
September 30, 2012
 
September 30, 2011
 
Amount
 
%
 
Amount
 
%
Net sales
$
211.2

 
100.0

 
$
202.1

 
100.0

Cost of goods sold
168.4

 
79.7

 
152.9

 
75.7

Gross profit
42.8

 
20.3

 
49.2

 
24.3

Operating expenses:
 
 
 
 
 
 
 
Selling, general and administrative
17.5

 
8.3

 
15.3

 
7.6

Research & development
0.7

 
0.3

 
0.8

 
0.4

Income from operations
24.6

 
11.6

 
33.1

 
16.4

Interest expense, net
1.3

 
0.6

 
1.5

 
0.7

Foreign exchange losses (gains), net
(1.8
)
 
(0.9
)
 
1.4

 
0.7

Provision for income taxes
8.4

 
4.0

 
11.3

 
5.6

Net income
$
16.7

 
7.9

 
$
18.9

 
9.4



 
Nine Months Ended
 
Nine Months Ended
 
September 30, 2012
 
September 30, 2011
 
Amount
 
%
 
Amount
 
%
Net sales
$
653.6

 
100.0

 
$
601.3

 
100.0

Cost of goods sold
512.6

 
78.4

 
445.6

 
74.1

Gross profit
141.0

 
21.6

 
155.7

 
25.9

Operating expenses:
 
 
 
 
 
 
 
Selling, general and administrative
49.7

 
7.6

 
46.9

 
7.8

Research & development
2.3

 
0.4

 
2.2

 
0.4

Income from operations
89.0

 
13.6

 
106.6

 
17.7

Interest expense, net
4.5

 
0.7

 
4.1

 
0.7

Foreign exchange losses (gains), net
(2.2
)
 
(0.3
)
 
2.0

 
0.3

Provision for income taxes
25.9

 
4.0

 
34.9

 
5.8

Net income
$
60.8

 
9.3

 
$
65.6

 
10.9



Three months ended September 30, 2012 compared to the three months ended September 30, 2011
Net Sales
Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the three months ended September 30, 2012 were $211.2 million, an increase of $9.1 million, or 4.5%, as compared to $202.1 million for the same period in 2011. Selling price increases had a positive effect on revenue of 2.3% or $4.6 million which included a 4.6% increase in Specialty Phosphates that was partially offset by lower pricing in GTSP & Other caused by fertilizer market prices that remained well below 2011 levels. Volumes increased 2.2% or $4.5 million on US/Canada Specialty Phosphates growth and higher GTSP & Other which in total were mostly offset by lower Mexico Specialty Phosphate volumes that were affected by a number of factors specific to the quarter, including weather related disruption and operating inefficiencies early in the quarter followed by scheduled maintenance outages which began later in the quarter.
The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to

Page 22 of 34



Table of Contents

date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.
The following table illustrates for the three months ended September 30, 2012 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:
 
 
Price
 
Volume/Mix
 
Total
Specialty Phosphates US & Canada
3.9
 %
 
6.7
 %
 
10.6
 %
Specialty Phosphates Mexico
6.5
 %
 
(21.7
)%
 
(15.2
)%
Total Specialty Phosphates
4.6
 %
 
(1.0
)%
 
3.6
 %
GTSP & Other
(16.4
)%
 
28.1
 %
 
11.7
 %
Total
2.3
 %
 
2.2
 %
 
4.5
 %
Note: Included within Specialty Phosphates US & Canada and Total Specialty Phosphates volume/mix variances were benefits of 4.4% and 3.3%, respectively, from the Kelatron business acquired in the fourth quarter of 2011 and the AMT business acquired in the third quarter of 2012.
The following table illustrates for the three months ended September 30, 2012 the percentage changes for net sales by Specialty Phosphates product lines compared with the prior year, including the effect of price and volume/mix changes:
 
 
Price
 
Volume/Mix
 
Total
Specialty Ingredients
4.6
 %
 
0.2
 %
 
4.8
 %
Food & Technical Grade PPA
11.5
 %
 
0.5
 %
 
12.0
 %
STPP & Detergent Grade PPA
(4.4
)%
 
(9.5
)%
 
(13.9
)%
Note: Included within Specialty Ingredients volume/mix variance was a 4.7% benefit from the Kelatron business acquired in the fourth quarter of 2011 and the AMT business acquired in the third quarter of 2012.

Gross Profit
Gross profit represents net sales less cost of goods sold. Gross profit for the three months ended September 30, 2012 was $42.8 million, a decrease of $6.4 million, or 13.0%, as compared to $49.2 million for the same period in 2011. Gross profit percentage decreased to 20.3% for the three months ended September 30, 2012 versus 24.3% for the same period in 2011. Gross profit was unfavorably affected by higher raw material costs, increased manufacturing cost which was partially offset by increased sales volume which had a combined unfavorable impact of $11.1 million. There was $1.1 million of increased expense for planned maintenance outages at our Geismar and Coatzacoalcos manufacturing facilities and $0.6 million for acquisition related fair value adjustments. Gross profit was favorably affected $4.6 million for higher selling prices, $0.7 million for lower depreciation, and $0.8 million of favorable exchange rate mostly from Mexican peso based costs. Included in 2011 was a charge of $0.3 million for the Mexican CNA matter.
Operating Expenses and Research and Development
Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the three months ended September 30, 2012 were $18.2 million, an increase of $2.1 million, or 13.0%, as compared to $16.1 million for the same period in 2011. The increase was primarily due to $1.0 million of expense in the newly acquired Kelatron and AMT businesses and $0.8 million of acquisition related expenses.
Operating Income
Operating income for the three months ended September 30, 2012 was $24.6 million, a decrease of $8.5 million, or 25.7%, as compared to $33.1 million for the same period in 2011. Operating income as a percentage of net sales decreased to 11.6% versus 16.4% for the same period in 2011, for the reasons noted above.
Interest Expense, net
Net interest expense, including deferred financing amortization expense, for the three months ended September 30, 2012 was $1.3 million, a decrease of $0.2 million, or 13.3% as compared to $1.5 million for the same period in 2011.

Page 23 of 34



Table of Contents

Foreign Exchange
Foreign exchange for the three months ended September 30, 2012 was a gain of $1.8 million as compared to a loss of $1.4 million for the same period in 2011. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. Consequently, foreign exchange gain or loss is recorded on remeasurement of non-U.S. dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the U.S. dollar and the amount of non-U.S. dollar denominated assets and liabilities increases or decreases.
Provision for Income Taxes
The effective income tax rate was 33% for the three months ended September 30, 2012 compared to 37% for the same period in 2011. The variance in the effective tax rate is due to increased earnings in lower tax jurisdictions.
Net Income
Net income for the three months ended September 30, 2012 was $16.7 million, a decrease of $2.2 million as compared to $18.9 million for the same period in 2011, due to the factors described above.

Nine months ended September 30, 2012 compared to the nine months ended September 30, 2011
Net Sales
Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the nine months ended September 30, 2012 were $653.6 million, an increase of $52.3 million, or 8.7%, as compared to $601.3 million for the same period in 2011. Selling price increases had a positive effect on revenue of 4.8%, or $29.0 million, with Specialty Phosphates up 7.5% on positive trends in all product lines, partially offset by lower pricing in GTSP & Other with fertilizer market prices well below 2011 levels. Volumes increased 3.9% or $23.3 million with GTSP & Other contributing the most but also positive trends seen in the more specialized Purified Phosphoric Acid and Specialty Ingredients product lines.
The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix. The following table illustrates for the nine months ended September 30, 2012 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:
 
 
Price
 
Volume/Mix
 
Total
Specialty Phosphates US & Canada
6.4
 %
 
3.6
 %
 
10.0
%
Specialty Phosphates Mexico
10.6
 %
 
(5.1
)%
 
5.5
%
Total Specialty Phosphates
7.5
 %
 
1.4
 %
 
8.9
%
GTSP & Other
(13.7
)%
 
21.3
 %
 
7.6
%
Total
4.8
 %
 
3.9
 %
 
8.7
%
Note: Included within Specialty Phosphates US & Canada and Total Specialty Phosphates volume/mix variances were benefits of 3.6% and 2.7%, respectively, from the Kelatron business acquired in the fourth quarter of 2011 and the AMT business acquired in the third quarter of 2012.

The following table illustrates for the nine months ended September 30, 2012 the percentage changes for net sales by Specialty Phosphates product lines compared with the prior year, including the effect of price and volume/mix changes:
 
 
Price
 
Volume/Mix
 
Total
Specialty Ingredients
6.9
%
 
1.4
 %
 
8.3
 %
Food & Technical Grade PPA
10.9
%
 
6.8
 %
 
17.7
 %
STPP & Detergent Grade PPA
5.9
%
 
(6.7
)%
 
(0.8
)%
Note: Included within Specialty Ingredients volume/mix was a 3.9% benefit from the Kelatron business acquired in the fourth quarter of 2011 and the AMT business acquired in the third quarter of 2012.

Page 24 of 34



Table of Contents


Gross Profit
Gross profit represents net sales less cost of goods sold. Gross profit for the nine months ended September 30, 2012 was $141.0 million, a decrease of $14.7 million, or 9.4%, as compared to $155.7 million for the same period in 2011. Gross profit percentage decreased to 21.6% for the nine months ended September 30, 2012 versus 25.9% for the same period in 2011. Gross profit was unfavorably affected by higher raw material costs partially offset by increased volumes which had a combined unfavorable impact of $52.0 million. There was a $0.5 million unfavorable impact for a planned maintenance outage at our Geismar facility offset by a net benefit of $2.6 million for scheduled maintenance outages at Coatzacoalcos. There was $2.4 million of out of period cost in Mexico during the nine months ended September 30, 2012, which was partially offset by revision to our estimates for the effect of contract terms on raw material pricing in 2012 of $1.2 million. Gross profit was favorably affected $29.0 million for higher selling prices, $7.1 million primarily due to the recording of a settlement with Rhodia on their liability for the charges to be paid to the Mexican water authority (CNA), $2.1 million favorable exchange rate impact mostly from Mexican peso based costs, and $2.4 million lower depreciation. Included in 2012 was $0.6 million for acquisition related fair value adjustments and in 2011 there was $3.6 million income for updates to the provision for the Mexican CNA Water Tax Claims.
Operating Expenses and Research and Development
Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the nine months ended September 30, 2012 were $52.0 million, an increase of $2.9 million, or 5.9%, as compared to $49.1 million for the same period in 2011. The increase was due to $2.1 million higher depreciation due to the ERP system that was put into service in the third quarter of 2011, $2.0 million increase for the Kelatron and AMT businesses and $0.8 million of acquisition related expenses, partially offset by $1.8 million lower non-cash stock compensation.
Operating Income
Operating income for the nine months ended September 30, 2012 was $89.0 million, a decrease of $17.6 million, or 16.5%, as compared to $106.6 million for the same period in 2011. Operating income as a percentage of net sales decreased to 13.6% versus 17.7% for the same period in 2011, for the reasons noted above.
Interest Expense, net
Net interest expense, including deferred financing amortization expense, for the nine months ended September 30, 2012 was $4.5 million, an increase of $0.4 million, or 9.8% as compared to $4.1 million for the same period in 2011.
Foreign Exchange
Foreign exchange gain for the nine months ended September 30, 2012 was $2.2 million as compared to a loss of $2.0 million for the same period in 2011. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. Consequently, foreign exchange gain or loss is recorded on remeasurement of non-U.S. dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the U.S. dollar and the amount of non-U.S. dollar denominated assets and liabilities increases or decreases.
Provision for Income Taxes
The effective income tax rate was 30% for the nine months ended September 30, 2012 compared to 35% for the same period in 2011. The variance in the effective tax rate is primarily due to the Rhodia settlement related to the Mexican CNA Water Tax Claims being recorded as a discrete item for income tax provision purposes in the first quarter of 2012 which had a 3% effect on the effective tax rate.
Net Income
Net income for the nine months ended September 30, 2012 was $60.8 million, a decrease of $4.8 million as compared to $65.6 million for the same period in 2011, due to the factors described above.

Page 25 of 34



Table of Contents


Segment Reporting
The Company reports its core Specialty Phosphates business separately from GTSP & Other. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA and STPP & Detergent Grade PPA. Kelatron and AMT are included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. GTSP & Other includes fertilizer co-product GTSP and other non-Specialty Phosphate products. The primary performance indicators for the chief operating decision maker are sales and operating income. The following table sets forth the historical results of these indicators by segment:
 
 
Three Months Ended
 
 
 
September 30,
2012
 
September 30,
2011
 
Net Sales % Change
Segment Net Sales
 
 
 
 
 
Specialty Phosphates US & Canada
$
144,664

 
$
130,850

 
10.6
 %
Specialty Phosphates Mexico
41,222

 
48,601

 
(15.2
)%
Total Specialty Phosphates
185,886

 
179,451

 
3.6
 %
GTSP & Other
25,302

 
22,651

 
11.7
 %
Total
$
211,188

 
$
202,102

 
4.5
 %
 
 
 
 
 
 
Segment Operating Income
 
 
 
 
 
Specialty Phosphates US & Canada
$
22,759

 
$
21,331

 
 
Specialty Phosphates Mexico
2,369

 
7,143

 
 
Total Specialty Phosphates
25,128

 
28,474

 
 
GTSP & Other (a)
(542
)
 
4,651

 
 
Total
$
24,586

 
$
33,125

 
 
 
 
 
 
 
 
Segment Operating Income % of net sales
 
 
 
 
 
Specialty Phosphates US & Canada
15.7
 %
 
16.3
%
 
 
Specialty Phosphates Mexico
5.7
 %
 
14.7
%
 
 
Total Specialty Phosphates
13.5
 %
 
15.9
%
 
 
GTSP & Other (a)
(2.1
)%
 
20.5
%
 
 
Total
11.6
 %
 
16.4
%
 
 
 
 
 
 
 
 
Depreciation and amortization expense
 
 
 
 
 
Specialty Phosphates US & Canada
$
5,732

 
$
4,864

 
 
Specialty Phosphates Mexico
3,670

 
4,909

 
 
Total Specialty Phosphates
$
9,402

 
9,773

 
 
GTSP & Other
1,160

 
1,753

 
 
Total
$
10,562

 
$
11,526

 
 

(a)
The three months ended September 30, 2011 includes a $0.3 million charge to earnings related to updates to the provision for the CNA Fresh Water Claims.



Page 26 of 34



Table of Contents

 
Nine Months Ended
 
 
 
September 30,
2012
 
September 30,
2011
 
Net Sales % Change
Segment Net Sales
 
 
 
 
 
Specialty Phosphates US & Canada
$
432,528

 
$
393,262

 
10.0
%
Specialty Phosphates Mexico
139,951

 
132,634

 
5.5
%
Total Specialty Phosphates
572,479

 
525,896

 
8.9
%
GTSP & Other
81,141

 
75,431

 
7.6
%
Total
$
653,620

 
$
601,327

 
8.7
%
 
 
 
 
 
 
Segment Operating Income
 
 
 
 
 
Specialty Phosphates US & Canada
$
70,262

 
$
77,613

 
 
Specialty Phosphates Mexico
17,156

 
12,358

 
 
Total Specialty Phosphates
87,418

 
89,971

 
 
GTSP & Other (a) (b)
1,590

 
16,593

 
 
Total
$
89,008

 
$
106,564

 
 
 
 
 
 
 
 
Segment Operating Income % of net sales
 
 
 
 
 
Specialty Phosphates US & Canada
16.2
%
 
19.7
%
 
 
Specialty Phosphates Mexico
12.3
%
 
9.3
%
 
 
Total Specialty Phosphates
15.3
%
 
17.1
%
 
 
GTSP & Other (a) (b)
2.0
%
 
22.0
%
 
 
Total
13.6
%
 
17.7
%
 
 
 
 
 
 
 
 
Depreciation and amortization expense
 
 
 
 
 
Specialty Phosphates US & Canada
$
17,280

 
$
14,897

 
 
Specialty Phosphates Mexico
11,233

 
12,814

 
 
Total Specialty Phosphates
$
28,513

 
27,711

 
 
GTSP & Other
3,605

 
4,732

 
 
Total
$
32,118

 
$
32,443

 
 

(a)
The nine month period ended September 30, 2012 includes a $7.1 million benefit to earnings primarily for the settlement with Rhodia on their liability for the charges to be paid to the CNA for the CNA Fresh Water Claims and a $2.4 million charge to earnings for out of period costs in Mexico.
(b)
The nine months ended September 30, 2011 includes a $3.6 million benefit to earnings related to updates to the provision for the CNA Fresh Water Claims.

Three months ended September 30, 2012 compared to the three months ended September 30, 2011
Segment Net Sales:
Specialty Phosphates US & Canada net sales increased 10.6% for the three months ended September 30, 2012 when compared with the same period in 2011. Selling prices increased 3.9% primarily in Specialty Ingredients and Food & Technical Grade PPA. Volumes increased 6.7% with increases across all product lines including a benefit of 4.4% for the Kelatron and AMT acquisitions.
Specialty Phosphates Mexico net sales decreased 15.2% for the three months ended September 30, 2012 when compared with the same period in 2011. Selling prices increased 6.5% primarily in Specialty Ingredients and Food & Technical Grade PPA. Volumes decreased 21.7% with decreases across all product lines that were affected by a number of factors specific to the quarter, including weather related disruption and operating inefficiencies early in the quarter followed by scheduled maintenance outages which began later in the quarter.
  

Page 27 of 34



Table of Contents

GTSP & Other net sales increased 11.7% for the three months ended September 30, 2012 when compared with the same period in 2011 on 28.1% higher volumes. Selling prices decreased 16.4% with fertilizer market prices well below 2011 levels.
Segment Operating Income Percentage of Net Sales:
The 60 basis point decrease in Specialty Phosphates US & Canada for the three months ended September 30, 2012 compared with the same period in 2011 is mainly due to increased raw material costs, expense for a maintenance outage in the current period, depreciation and acquisition related fair value adjustments which combined for a 370 basis point decrease in margin percent. This was partially offset by increased selling prices which increased margins by 310 basis points.
The 900 basis point decrease in Specialty Phosphates Mexico for the three months ended September 30, 2012 compared with the same period in 2011 is mainly due to lower volumes, higher raw material costs which exceeded lower operating expenses and depreciation contributing a 1,430 basis point decrease in margins. This was partially offset by increased selling prices which increased margins by 530 basis points.
The 2,260 basis point decrease in GTSP & Other for the three months ended September 30, 2012 compared with the same period in 2011 is primarily due to lower selling prices which decreased margin by 1,550 basis points. Higher raw material costs exceeded lower manufacturing expenses and depreciation which decreased margins by 830 basis points. The charge included in 2011 for the Mexican CNA matter increases margin by 120 basis points.
Nine months ended September 30, 2012 compared to the nine months ended September 30, 2011
Segment Net Sales:
Specialty Phosphates US & Canada net sales increased 10.0% for the nine months ended September 30, 2012 when compared with the same period in 2011. Selling prices increased 6.4% primarily in Specialty Ingredients and Food & Technical Grade PPA. Volumes increased 3.6% due to the benefit of the Kelatron and AMT acquisitions.
Specialty Phosphates Mexico net sales increased 5.5% for the nine months ended September 30, 2012 when compared with the same period in 2011. Selling prices increased 10.6% with increases across all product lines. Volumes decreased 5.1% primarily in STPP & Detergent Grade PPA.
GTSP & Other net sales increased 7.6% for the nine months ended September 30, 2012 when compared with the same period in 2011, with 21.3% higher volumes. This was partially offset by 13.7% lower selling prices caused by fertilizer market prices that were well below 2011 levels.
Segment Operating Income Percentage of Net Sales:
The 350 basis point decrease in Specialty Phosphates US & Canada for the nine months ended September 30, 2012 compared with the same period in 2011 is mainly due to increases in raw material costs, manufacturing expenses, depreciation, operating expenses, and a maintenance outage in the current year which combined for an 840 basis point decrease in margins. Partially offsetting was increased selling prices which increased margins by 490 basis points.
The 300 basis point increase in Specialty Phosphates Mexico for the nine months ended September 30, 2012 compared with the same period in 2011 is mainly due to increased selling prices which increased margins by 870 basis points. Higher raw material costs were partially offset by lower manufacturing expenses, operating expenses, depreciation, and the net benefit from the maintenance outages in both years combining for a 570 basis point decrease in margins.
The 2,000 basis point decrease in GTSP & Other for the nine months ended September 30, 2012 compared with the same period in 2011 is primarily due to lower selling prices which decreased margins by 1,230 basis points. Higher raw material costs which exceeded a benefit from the 2011 maintenance outage and lower depreciation contributed an 870 basis point decrease in margins. The net effect of the 2012 versus 2011 benefit of $3.5 million for the settlement with Rhodia on their liability for the charges to be paid to the CNA increased margins by 460 basis points. Out of period costs in the current period, net of revision to our estimates for the effect of contract terms on raw material pricing in 2012, decreased margins by 360 basis points.

Page 28 of 34



Table of Contents



Liquidity and Capital Resources
The following table sets forth a summary of the Company’s cash flows for the periods indicated.
 
(Dollars in millions)
Nine months ended
 
September 30,
2012
 
September 30,
2011
Operating Activities
$
100.8

 
$
75.4

Investing Activities
(43.1
)
 
(27.2
)
Financing Activities
(56.4
)
 
(25.7
)

Nine months ended September 30, 2012 compared to nine months ended September 30, 2011
Net cash provided by operating activities was $100.8 million for the nine months ended September 30, 2012 as compared to $75.4 million for 2011, an increase of $25.4 million. The increase in operating activities cash resulted primarily from favorable changes of $41.4 million in working capital partially offset by unfavorable changes of $10.5 million in non-cash adjustments to income, $0.7 million in other long term assets and liabilities and $4.8 million in net income as described earlier.
The change in working capital is a source of cash of $9.6 million in 2012 compared to a use in 2011 of $31.8 million, an increase in cash of $41.4 million, primarily the result of reduced accounts receivable and inventory levels in 2012 compared to increased levels in 2011, offset partially by higher creditable tax balances for our Mexico entities and by reduced levels of current liabilities. The higher creditable tax balances are due to required prepayments of income taxes and slowness of value added tax, or VAT refunds due to the Company from the Mexico government. The Company believes all VAT amounts due from the Mexico government are fully collectible.
Net cash used for investing activities was $43.1 million for the nine months ended September 30, 2012, compared to $27.2 million for 2011 an increase of $15.9 million. The change is mainly due to the $27.1 million investment in AMT made in the third quarter of 2012. This was partially offset by $11.2 million lower capital spending mainly on the company's ERP project and an expansion project at Nashville, TN.
Management projects total 2012 capital expenditures to be approximately $25 million.
Innophos currently estimates that full exploration costs to a proven reserves standard for its Baja California mining concessions could require expenditures of $10 to $15 million over a period, currently estimated at three to five years, inclusive of expenditures to date. This estimate includes mineral rights payments, taxes, mineral resource measurement, beneficiation process design and completion of feasibility studies. Full expenditures would only occur if interim milestone goals were successfully attained. Combined 2010 and 2011 expenditures on the exploration of the Baja California Sur concession deposits were approximately $2.4 million, and management currently expects to spend an additional $2-4 million in 2012-2013 above the previous trend rate to accelerate evaluations of its Santo Domingo concession. Innophos intends to seek one or more partners for these efforts, but anticipates no difficulties in completing the exploration phase without a partnership.
Net cash from financing activities for the nine months ended September 30, 2012, was a use of $56.4 million, compared to a use of $25.7 million in 2011, an increase in the use of cash of $30.7 million. This was mainly due to $27.0 million lower borrowings, $2.7 million higher dividend payments, and $1.1 million increased common stock repurchases.
Innophos and its subsidiaries and affiliates may from time to time seek to acquire or otherwise retire outstanding debt through privately negotiated transactions, exchanges or otherwise. Debt repurchases or exchanges, if any, will depend on prevailing market conditions, Company liquidity requirements, restrictive financial covenants and other factors applicable at the time. The amounts involved may be material.
On September 30, 2012, the Company had cash and cash equivalents outside the United States of $28.6 million, or 78% of the Company's balance. Further, the foreign cash amounts are not restricted by law to be used in other countries. Our current operating plan does not include repatriation of any of the cash and cash equivalents held outside the United States to fund the United States operations. However, in the event we do repatriate cash and cash equivalents held outside of the United States, we may be required to accrue and pay United States taxes to repatriate these funds.

Page 29 of 34



Table of Contents

The Company's available financial resources allow for the continuation of dividend payments, pursuit of several “bolt-on” acquisition projects and further geographic expansion initiatives. We further believe that on-hand cash combined with cash generated from operations, including our Mexican operations, and availability under our revolving line of credit, will be sufficient to meet our obligations such as debt service, tax payments, capital expenditures and working capital requirements for at least the next twelve months. We expect to fund all these obligations through our existing cash and our future operating cash flows. However, future operating performance for the Company is subject to prevailing economic and competitive conditions and various other factors that are uncertain. If the cash flows and other capital resources available to the Company, such as its revolving loan facility, are insufficient to fund our debt and other liquidity needs, the Company may have to take alternative actions that differ from current operating plans.
On February 27, 2012 the Company's Board of Directors declared an increase to its dividend from $0.25 per share to $0.27 per share to holders of record on April 16, 2012. On October 26, 2012 the Company's Board of Directors declared an increase to its dividend from $0.27 per share to $0.35 per share to holders of record on November 16, 2012.
On July 17, 2012, Innophos, Inc. purchased for cash 100% of the equity of AMT Labs, Inc. and an affiliated real estate company holding all AMT real property, including unused land and buildings to support future expansion. The combined purchase price was $27 million, with $19.5 million being allocated to the AMT purchase and $7.5 million being allocated to the real estate entity. The transaction includes potential for additional consideration of up to $3 million contingent upon success in developing new market opportunities. The price was funded from our revolving line of credit as well as cash from operations.

Critical Accounting Estimates and Policies
There have been no material changes from the critical accounting estimates previously disclosed in our 2011 Annual Report on Form 10-K.
 
ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to certain market risks as part of our ongoing business operations. Primary exposures include changes in interest rates, as borrowings under our Loan Agreement will bear interest at floating rates based on LIBOR plus an applicable borrowing margin. We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status. For fixed-rate debt, interest rate changes do not affect earnings or cash flows. Conversely, for floating-rate debt, interest rate changes generally affect our earnings and cash flows, assuming other factors are held constant.
At September 30, 2012, we had $92.0 million principal amount of variable-rate debt and a $125.0 million revolving credit facility, of which $25.0 million was outstanding, both of which approximate fair value, determined using level 2 inputs within the fair value hierarchy. Total remaining availability was $98.1 million, taking into account $1.9 million in face amount of letters of credit issued under the sub-facility. In the third quarter of 2010 we entered into an interest rate swap with an original notional amount of $100 million adjusting quarterly consistent with the Term Loan, with a fixed rate of 1.994% plus the applicable margin on the debt, expiring in August 2015. The Company exercised its right to cancel the swap with no fee on September 28, 2012.
Changes in economic conditions could result in higher interest rates, thereby increasing our interest expense on our revolving line of credit. Changes in economic conditions may also result in lower operating income, reducing our funds available for capital investment, operations or other purposes. In addition, a substantial portion of our cash flow has been used to service debt and fund working capital needs, which may affect our ability to make future acquisitions or capital expenditures. We may from time to time use interest rate protection agreements to minimize our exposure to interest rate fluctuation. Regardless of hedges, we may experience economic loss and a negative impact on earnings or net assets as a result of interest rate fluctuations. Based on $117.0 million outstanding borrowings as floating rate debt under our revolving credit facility, an immediate increase of one percentage point would cause an increase to interest expense of approximately $1.2 million per year.
From time to time, we may enter into longer term natural gas supply contracts in an effort to eliminate some of the volatility in our energy costs. Our natural gas spending for 2012 is estimated to be less than 2% of cost of goods sold. We did enter into a financial hedge for approximately 75% of our 2012 U.S. & Canada natural gas requirements, to reduce price volatility using fixed price contracts. At September 30, 2012, there was approximately zero fair value for these natural gas contracts.
We do not currently hedge our currency rate risks.

Page 30 of 34



Table of Contents

We believe that our concentration of credit risk related to trade accounts receivable is limited since these receivables are spread among a number of customers and are geographically dispersed. No customer accounted for more than 10% of our sales in the last 3 years.
Foreign Currency Exchange Rates
The U.S. Dollar is the functional currency of the Canadian and Mexican operations. Accordingly, these operations’ monetary assets and liabilities are translated at current exchange rates, non-monetary assets and liabilities are translated at historical exchange rates, and revenue and expenses are translated at average exchange rates and at historical exchange rates for the related revenue and expenses of non-monetary assets and liabilities. All transaction gains and losses are included in net income.
Our principal source of exchange rate exposure in our foreign operations consists of expenses, such as labor expenses, which are denominated in the foreign currency of the country in which we operate. A decline in the value of the U.S. Dollar relative to the local currency would generally cause our operational expenses (particularly labor costs) to increase (conversely, a decline in the value of the foreign currency relative to the U.S. Dollar would cause these expenses to decrease). We believe that normal exchange rate fluctuations consistent with recent historical trends would have a modest impact on our expenses, and would not materially affect our financial condition or results of operations. Nearly all of our sales are denominated in U.S. Dollars and our exchange rate exposure in terms of sales revenues is minimal.
Inflation and changing prices
Our costs and expenses will be subject to inflation and price fluctuations. Significant price fluctuations in raw materials, freight, and energy costs, if not compensated for by cost savings from production efficiencies or price increases passed on to customers could have a material effect on our financial condition and results of operations.
Off-Balance Sheet Arrangements
We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as “structured finance or special purpose entities”, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

ITEM 4.
CONTROLS AND PROCEDURES
Disclosure Control and Procedures
The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) that are designed to provide reasonable assurance that information required to be reported in the Company's consolidated financial statements and filings is recorded, processed, summarized and reported within the periods specified in the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to the Company's management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.
As of September 30, 2012 the Company completed an evaluation under the supervision and with the participation of the Company's management, including the Company's Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon that evaluation, the Principal Executive Officer and Principal Financial Officer concluded that the Company's disclosure controls and procedures are effective at the reasonable assurance level.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during or with respect to the third quarter of 2012 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.


Page 31 of 34



Table of Contents

PART II
 
ITEM 1.
LEGAL PROCEEDINGS
Note 12 of Notes to Consolidated Condensed Financial Statements in “Item 1. Financial Statements" contained in this Quarterly Report on Form 10-Q is incorporated herein by reference.
 
ITEM 1A.
RISK FACTORS
There have been no material changes from the risk factors previously disclosed in our 2011 Annual Report on Form 10-K.
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3.
DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4.
MINE SAFETY DISCLOSURES
None.
ITEM 5.
OTHER INFORMATION
None.

ITEM 6.
EXHIBITS
a) Exhibits. The following exhibits are filed or furnished as part of this report:
Exhibit No.
 
Description
31.1
 
Certification of Principal Executive Officer dated November 8, 2012 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
 
Certification of Principal Financial Officer dated November 8, 2012 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*
 
Certification of Principal Executive Officer dated November 8, 2012 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*
 
Certification of Principal Financial Officer dated November 8, 2012 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
*
Not to be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liability of that section, nor deemed to be incorporated by reference into any filing under that Act or the Securities Act of 1933.


Page 32 of 34



Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INNOPHOS HOLDINGS, INC.
 
 
 
/s/ Randolph Gress
By:
Randolph Gress
Its:
Chief Executive Officer and Director
 
(Principal Executive Officer)
 
Dated:
November 8, 2012
 
INNOPHOS HOLDINGS, INC.
 
 
 
/s/ Neil I. Salmon
By:
Neil I. Salmon
Its:
Vice President and Chief Financial Officer
 
(Principal Financial Officer)
 
Dated:
November 8, 2012


Page 33 of 34



Table of Contents

EXHIBIT INDEX
Exhibit No.
  
Description
31.1
  
Certification of Principal Executive Officer dated November 8, 2012 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
  
Certification of Principal Financial Officer dated November 8, 2012 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1
  
Certification of Principal Executive Officer dated November 8, 2012 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2
  
Certification of Principal Financial Officer dated November 8, 2012 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002



Page 34 of 34